Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
AWAKN LIFE SCIENCES CORP
954Current price
0.047 EUR
0 EUR (0.00%)
Last closed
0.11 EUR
Company
–
ISIN
CA05455W1086
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
3 374 059 EUR
Yield for 12 month
-71.30 %
1Y
3Y
5Y
10Y
15Y
954
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavioural therapy (CBT) which is in phase 3 trials to treat severe Alcohol Use Disorder (AUD); AWKN-002, a novel MAT consisting of a patent pending proprietary S"ketamine oral thin film, and manualized relapse prevention CBT to treat AUD; and MDMA/Zydis, an investigational medicinal product entactogen that acts as a releaser and reuptake inhibitor of serotonin, norepinephrine, and dopamine. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD; and with Graft Polymer (UK) PLC to develop chemical entity series programme for trauma-related mental health disorders. Awakn Life Sciences Corp. is headquartered in Toronto, Canada. Address: 217 Queen Street West, Toronto, ON, Canada, M5V 0R2
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Key Figures 954
1 year
3 years
5 years
10 years
EBITDA
-3 458 260 EUR
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-93.88 %
PEG Ratio
–
Return On Equity TTM
-8495.3 %
Wall Street Target Price
–
Revenue TTM
95 322 EUR
Book Value
-0.046 EUR
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
72.4 %
Dividend Yield
–
Gross Profit TTM
-274 710 EUR
Earnings per share
-0.079 EUR
Diluted Eps TTM
-0.079 EUR
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 954
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 954
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 954
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
48.8594
Price Sales TTM
35.3964
Enterprise Value EBITDA
-1.0972
Price Book MRQ
9.2166
Financials 954
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 954
For 52 weeks
0.027 EUR
0.19 EUR
50 Day MA
0.064 EUR
Shares Short Prior Month
–
200 Day MA
0.082 EUR
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart